Genentech taps Caris in up to $1.1B oncology AI deal as year-end deal rush continues
Roche subsidiary Genentech has joined the late-December dealmaking surge, striking a multi-year cancer collaboration with Caris Life Sciences that could be worth up to $1.1 billion as the pharma looks to replenish its oncology discovery engine through external innovation.
The agreement signed yesterday grants Caris the right to receive $25 million in upfront and near-term payments, with the bulk of the value tied to R&D, regulatory, commercial, and sales milestones, and royalties on any resulting products. The partnership centers on Caris Discovery, the company’s AI-driven therapeutic research arm.
The collaboration will focus on identifying and validating novel oncology targets in solid tumors, leveraging Caris’ massive multimodal database built from nearly 500,000 tumor samples paired with molecular and clinical data. Genentech aims to translate those insights into first-in-class precision medicines, reinforcing its long-standing bet on data-driven oncology.
Caris, best known for its molecular diagnostics business, has increasingly positioned itself as a “techbio” discovery partner. Its tissue-based platform and AI analytics have already drawn partnerships with Merck KGaA and Moderna, expanding its footprint beyond diagnostics into early drug discovery.
The deal lands amid an unusually dense stretch of year-end biotech transactions. Sanofi has rolled out multiple immunology partnerships in recent days, while Pfizer inked a separate agreement with Adaptive Biotechnologies, underscoring big pharma’s urgency to secure differentiated science before the calendar flips.
For Genentech, the Caris pact also marks a contrast with its summer retrenchment. Earlier this year, the Roche unit exited several oncology collaborations, including a high-profile termination of a cancer cell therapy deal with Adaptive, and carried out multiple rounds of cost-cutting and layoffs. The Caris deal signals a more selective, data-centric approach to rebuilding its pipeline rather than broad internal expansion.
“Collaborations with partners such as Caris allow us to pursue future innovation for patients with unmet needs,” Roche head of corporate business development Boris Zaïtra said, framing the partnership as part of Genentech’s long-term oncology strategy.
As 2025 draws to a close, the Genentech-Caris alliance adds another data-heavy, milestone-laden pact to a December deal spree that shows little sign of slowing.
